Charles River Laboratories International (NYSE:CRL) updated its FY 2026 earnings guidance. The company provided EPS guidance of 11.450-11.450 for the period, compared to the consensus estimate of 11.330. The company also issued revenue guidance of $3.9 billionillion-$3.9 billionillion, compared to the consensus estimate of $3.9 billionillion.